1
Ravindra Babu Bollu, Jakob Felding, Simon Feldbæk Nielsen, Jens Christian Højland Larsen: Phosphodiesterase inhibitors. Leo Pharma, Birch Stewart Kolasch & Birch, December 25, 2012: US08338431 (1 worldwide citation)

The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions com ...


2
Simon Feldbæk Nielsen: Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors. Leo Pharma, Birch Stewart Kolasch & Birch, March 17, 2015: US08980905 (1 worldwide citation)

Compounds of the general formula (I) wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—; R3 is —CHF2, —CF3, —OCHF2, —OCF3, —S ...


3
Søren Christian Schou, Daniel Rodriguez Greve, Simon Feldbæk Nielsen, Jens Bjørn Jensen, Kevin Neil Dack: Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof. LEO PHARMA, Birch Stewart Kolasch & Birch, January 12, 2016: US09233964

The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK ...


4
Simon Feldbæk Nielsen, Daniel Rodriguez Greve, Carsten Ryttersgaard, Gunnar Grue Sørensen, Erik Rytter Ottosen, Tina Dahlerup Poulsen, Søren Christian Schou, Anthony Murray: Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors. LEO PHARMA, Birch Stewart Kolasch & Birch, May 24, 2016: US09346809

The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therap ...


5
Simon Feldbæk Nielsen, Thomas Vifian, Anne Marie Horneman, Jesper Færgemann Lau: Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases. Leo Pharma, Birch Stewart Kolasch & Birch, February 10, 2015: US08952162

The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.


6
Simon Feldbæk Nielsen, Anne Marie Horneman, Jesper Lau, Jens Christian Højland Larsen: Biaryl phosphodiesterase inhibitors. LEO PHARMA, Birch Stewart Kolasch & Birch, June 9, 2015: US09051290

Novel biaryl compounds with phosphodiesterase inhibitory activity of general formula (I) below, wherein R1, R2, R3, X, Y, Z1, Z2, Z3, and Z4 have the meanings defined herein, as well as their use as therapeutic agents in the treatment of inflammatory diseases and conditions are described herein.


7
Dan Peters, Gunnar M Olsen, Elsebet Østergaard Nielsen, Philip K Ahring, Simon Feldbæk Nielsen, Tino Dyhring Jørgensen: Aryl and heteroaryl diazabicycloalkanes, their preparation and use. Neurosearch, Birch Stewart Kolasch & Birch, June 13, 2006: US07060699

The present invention relates to novel aryl and heteroaryl diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the inventio ...


8
Jakob Felding, Simon Feldbæk Nielsen: Substituted acetophenones useful as PDE4 inhibitors. Leo Pharma, Birch Stewart Kolasch & Birch, April 3, 2012: US08148537

The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and Xi and X2 independently of each other represent C and form part of an additional ...


9
Jakob Felding, Simon Feldbæk Nielsen: Substituted acetophenones useful as PDE4 inhibitors. Leo Pharma, Birch Stewart Kolasch & Birch, December 4, 2012: US08324394

The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and X1 and X2 independently of each other represent C and form part of an additional ...


10
Jakob Felding, Simon Feldbæk Nielsen: Substituted acetophenones useful as PDE4 inhibitors. Leo Pharma, Birch Stewart Kolasch & Birch, July 30, 2013: US08497380

The present invention relates to a compound according to formula: (1); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and X1 and X2 independently of each other represent C and form part of an additional ...